Login to Your Account



Pharma: Clinic Roundup


Tuesday, August 6, 2013
• Sanofi Pasteur Ltd., the vaccines division of Sanofi SA, of Paris, initiated a Phase III program called Cdiffense to evaluate the safety, immunogenicity and efficacy of its investigational vaccine to prevent primary symptomatic Clostridium difficile infection (CDI) in at-risk individuals.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription